Slap on the wrist for Endo over FTC pay-for-delay deals

24 January 2017

Endo International (Nasdaq: ENDP) has resolved its antitrust dispute with the US Federal Trade Commission (FTC), via a joint motion filed in a Californian district court.

In a court action last March the FTC alleged that Endo entered into pay-for-delay deals in order to throttle access to generic versions of its pain drugs Lidoderm (lidocaine) and Opana ER (oxymorphone).

The company has now reached an agreement with the FTC which covers any future settlement of patent infringement litigation for a period of 10 years.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK